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Abstract
Background: Whole-protein extracts from peripheral blood leukocytes are ideal for basic and clinical research.
However, lack of a simple preparation technique has limited the use of such extracts. The aim of this study is to
develop a simple and easy system that can selectively obtain leukocyte extracts without hemoglobin.
Methods: A filter that captures the leukocytes but not RBCs was set at the bottom of a 10-mL medical syringe by
sandwiching it between plastic stoppers. The capturing efficiency of leukocytes with this tool, called LeukoCatch,
was examined using human macrophage cells (MONO-MAC-6). The abilities of LeukoCatch system to capture the
leukocyte proteins and to remove the hemoglobin from RBCs were tested by western blot analysis using human
blood samples.
Results: This study presents the development of LeukoCatch, a novel tool that allows the preparation of leukocyte
extracts from blood samples within 3 min without centrifugation. Tissue-cultured human macrophage cells were
tested to determine the optimal filter numbers and pass-through frequencies of LeukoCatch, which was then
applied to 2-mL blood samples. Samples were passed 2~5 times through a LeukoCatch equipped with 5 filters,
washed twice with phosphate-buffered saline for red cell removal, and leukocyte proteins were extracted with 0.5
mL of elution buffer. Western blot analysis of the purified extract indicated that more than 90% of hemoglobin
was removed by the LeukoCatch and that the protein recovery rate of leukocytes was at least 4 times better than
that of the conventional centrifugation method.
Conclusion: We conclude that LeukoCatch is useful not only for diagnosis at the bedside but also for basic
research using blood samples or tissue culture cells.
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Background
Peripheral blood is an ideal surrogate tissue for disease
diagnosis and prognosis. Extensive data have been accu-
mulated from the genome-wide gene-expression profil-
ing of patient peripheral blood mononuclear cells
(PBMCs) and their leukocyte subpopulations using DNA
m i c r o a r r a ya n a l y s e s[ 1 , 2 ]i naw i d er a n g eo fd i s e a s e s ,
including cancer [3,4] and autoimmune diseases [5].
Moreover, novel approaches or revolutionary tools for
transcriptomics are rapidly emerging [6]. These data
reveal the up- or down-regulated genes that can serve as
potential RNA diagnostic markers of relevant diseases
[7-10]. If the marker gene products (mostly proteins)
could be detected by antibodies using the extracts of
leukocyte subpopulations in the PBMCs, the transcip-
tome data would be practically useful for bedside diag-
nosis. Generally, the instrumentation required for RNA
diagnostics is not routinely available at the bedside or in
a common clinical facility.
Most antibody-based diagnostics target proteins
secreted into the serum or protruding from the cell
membrane surface. Such targets are easily detected by
specific antibodies via enzyme-linked immunosorbent
assay (ELISA) or dot blot analysis using the supernatant
or sediments of the blood sample. To efficiently analyze
leukocyte protein extracts for expression profiling by
specific antibodies, the white blood cells (WBCs) or leu-
kocytes must be separated from the red blood cells
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blood volume. Red blood cells contain abundant iron-
rich hemoglobin, which can hamper the analysis of the
comparatively small amount of leukocyte proteins.
The separation of RBCs from leukocytes has been pri-
marily based on methodology established through the
pioneering work of Bøyum [11]. Separation media con-
sisting of a mixture of Ficoll 400 (or Percoll) and an
iodinated density gradient medium have been very
widely used to purify human leukocytes in basic
research and in routine diagnostic studies. Nevertheless,
variable extract recovery rates and/or possible changes
in the expression profiles during the several-hour
separation procedure can disturb the data reproducibil-
ity. Moreover, the leukocyte separation procedure
requires an expensive centrifugation facility that is not
routinely available at the bedside. Thus, a quick, easy,
inexpensive, and efficient method for the purification of
leukocyte extracts is needed.
In the present study, we present LeukoCatch, a novel
tool for the centrifugation-free purification of leukocyte
extracts from whole blood. LeukoCatch consists of a layer
of filters held at the bottom of a syringe, which captures
leukocytes but not RBCs from a blood sample. Captured
leukocytes are washed by phosphate-buffered saline (PBS)
and the protein extract of leukocytes were collected as the
flow-through fraction that was obtained by flushing the fil-
ter with extraction buffer. Western blot analyses revealed
that the collected extracts lacked most RBC components
and retained a sufficient amount of leukocyte-derived pro-
teins. We propose that LeukoCatch is useful not only for
diagnosis at the bedside but also for basic research.
Results
Structure of LeukoCatch and its usage
Since RBC hemoglobin and serum immunoglobulin
comprise most of the protein in blood cells, they must
be removed to analyze the variation of protein compo-
nents in leukocytes. A LeukoCatch filter (Pall, Leuko-
sorb B Medium, LKB-3R) was set at the bottom of a 10-
mL medical syringe by sandwiching it between plastic
stoppers (Figure 1A). This filter is expected to capture
the leukocytes but not RBCs or platelets, and has been
successfully used at the bedside (Leukotrap filter; see
http://www.pall.com/medical_39479.asp) to prepare leu-
kocyte-depleted platelet concentrates from whole blood
[12-14]. We surmised that the leukocytes but not RBCs
of the peripheral blood would be efficiently captured by
passing through a small number of layered filters (Figure
1B-i) by moving the piton up (steps a and c)a n dd o w n
(steps b and d)b yh a n d ,a n dt h a tt h eh e m o g l o b i na n d
immunoglobulin would be removed by washing the filter
with PBS (Figure 1B-ii) with upward (steps e and g) and
downward (steps f and h) piton movement. The whole-
protein extract, collected by rinsing the filter with EB by
upward (step i) and downward (step j) piton handling,
would be ready for further examination by western or
dot-blot analysis (Figure 1B-iii).
Optimal filter number in the LeukoCatch to capture
macrophage cells
To determine the optimal number of filters in the Leu-
koCatch, we examined the capturing efficiency of
human macrophage cells (MONO-MAC-6). When the
number of filters was varied from zero (NT: non-trea-
ted) to ten and the number of captured cells was
counted by FACS, > 60% of cells were captured by a
LeukoCatch equipped with 5, 7, or 10 filters after taking
in and expelling the MONO-MAC-6 cells in the med-
ium once (Figure 2A).
Western blot analysis was performed using antibodies
for GAPDH and Erk1/2, which are expressed by MONO-
MAC-6 cells, using a 5-μL extract (10% of total) of
escaped cells. The amount of passed-through proteins
was reduced relative to the number of filters used, as
judged by direct observation (Figure 2B) or quantification
of the band intensities by using the Image-J software
(Figure 2C). Similar western analysis using a 5-μL extract
(10% of total) of captured cells indicated that the Leuko-
Catch with > 3 filters was practically useful for capturing
t h e s ep r o t e i n s .T h eb a n di n t ensities were saturated due
to abundant captured proteins when 3 to 10 filters were
employed, revealing the excellent capture efficiency of
t h eL e u k o C a t c h .S i n c ep a s s i n gt h es a m p l et h r o u g h7o r
10 filters is practically difficult (due to the sticky move-
ment of the syringe plunger), we used 5 filters (i.e., a “5-
filtered LeukoCatch”) for further experiments.
Optimal passage frequency through the LeukoCatch for
macrophage cells
We next varied the number of times the MONO-MAC-6
cells were passed through the 5-filtered LeukoCatch (i.e.,
the “passage frequency”). FACS analysis indicated that 2-5
passages effectively captured > 60% of cells. Western ana-
lysis for both GAPDH and Erk1/2 indicated that the
amount of passed through (escaped) proteins was reduced
relative to the passage frequency through the 5-filtered
LeukoCatch (Figure 3A). In contrast, the ratio of the cap-
tured GAPDH increased relative to the passage frequency
(Figure 3B). The amount of captured Erk1/2 was unal-
tered, probably due to saturation since Erk1/2 is abundant
in MONO-MAC-6 cells. These results indicate that use of
≥ 5 passes through the 5-filtered LeukoCatch is preferable.
Effect of filter number and passage frequency on
leukocyte capture from blood samples
To assess the optimal number of filters in the Leuko-
Catch for blood samples, we examined the leukocyte
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logic analysis of the blood samples was performed
immediately after passing each sample once through the
LeukoCatch equipped with various numbers of filters.
The number of passed-through WBCs, leukocytes, and
other leukocyte subpopulations decreased with an
increasing number of filters (Figure 4A). Notably, when
the blood was passed through 5 times with the 5-filtered
LeukoCatch, we obtained a similarly excellent efficiency
as was found with the 10-filtered LeukoCatch. Similar
capture efficiencies were obtained for the lymphocyte
(LY), monocyte (MO), neutrophil (NE), and PLT subpo-
pulations (Figure 4B-E). No RBCs appeared to be
captured by the LeukoCatch (Figure 4F). Slight increase
in the number of RBCs is probably due to the
fragmentation, namely, the RBCs fragmented during the
passage of the filters were counted as independent RBCs
by the hematology analyzer used in this experiment.
These results indicate that leukocyte cells are efficiently
captured by the 5-filtered LeukoCatch.
We next varied the passage frequencies of blood
samples through the 5-filtered LeukoCatch. Leukocytes
were captured more efficiently with an increasing pas-
sage frequency (Figure 5A). Similar results were
obtained for other leukocytes and PLTs, although
some of their efficiencies appeared to be saturated,
probably because of the limited numbers of their
populations (Figure 5C-E). In contrast, no RBCs were
captured even by passing 5 times through the 5-filtered
LeukoCatch (Figure 5F).
Figure 1 Schematic drawings of the LeukoCatch system and its usage. (A) Structure of the LeukoCatch system in which the stacked filters
are installed between the stoppers at the bottom of a commercially available syringe. An enlarged view of the stacked configuration of the
filtering system is shown in an inset. (B) A schematic drawing for a protocol for preparation of leukocyte (or PBMC) extract from 2 ml blood
sample. The protocol consists of three procedures: capture of leukocyte by the LeukoCatch filters (i), leukocyte wash by PBS (ii), and collection of
leukocyte extract in the elution buffer of the flow-through. (iii) The leukocyte extract in the flow-through fraction is ready for examination (e.g.,
by western blot analysis or ELISA). Thin horizontal arrows show the flow of the procedure (from step a, to step j). Thick vertical arrows indicate
the multiple movements of the piston to allow the blood (i), PBS (ii) or elution buffer (iii) pass through the stacked filters in the LeukoCatch
system. In each step, the piston was moved up (steps a, c, e, g and i) or down (steps b, d, f, h and i) by hand. The whole procedure may be
completed within 3 min.
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Page 3 of 11Figure 2 Effect of the filter number on macrophage capture by the LeukoCatch. (A) Human macrophage (MONO-MAC-6) cells were
examined as a surrogate of leukocytes in the blood. Cells were subjected to serial passage (twice) of the same syringe (LeukoCatch system) that
was equipped with 0, 1, 3, 5, 7 or 10 filters. NT signifies the non-treated blood sample. The “0” differs from NT because in “0”, the blood sample
was passed through the LeukoCatch system with a zero filer. The bar graphs represent the number of macrophage cells (flow-through) that
were not captured with the filters. Cell counts were obtained by FACS (n = 4). (B) Western blot analysis by anti-GAPDH and anti-Erk1/2
antibodies using a 5-μL extract (10% of total) of cells escaped from or captured by the indicated numbers of filters in the LeukoCatch. (C) The
bar graphs represent the relative intensity of the band signals measured by using the Image-J software, which were given as percentage of the
starting material (NT: non-treated).
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Page 4 of 11Figure 3 Effect of the passage frequency on macrophage capture by LeukoCatch. (A) Human macrophage (MONO-MAC-6) cells were
subjected to serial passage (1, 2, 3, 4 or 5 times) of the same syringe (LeukoCatch system) with a stack of 5 filters. NT, non-treated. The bar
graphs represent the number of macrophage cells (flow-through) that were not captured with the LeukoCatch system after serial passage. Cell
numbers were counted by FACS (n = 4). (B) Western blot analysis with anti-GAPDH and anti-Erk1/2 antibodies using a 5-μL extract (10% of total)
of cells that escaped from or were captured by the LeukoCatch filters, after being passed through the indicated number of times. (C) The bar
graphs represent the relative intensity of the band signals measured by using the Image-J software, which were given as percentage of the
starting material (NT: non-treated).
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efficiency
To assess the extent of protein capture by the 5-filtered
LeukoCatch system for blood samples, we performed
western blot analysis for the proteins retained on the fil-
ter (retentate) after PBS wash, and then eluted into the
flow-through fraction (Figure 1b, step j). We used anti-
GAPDH and -Erk1/2 antibodies to detect proteins that
exist in both leukocytes and RBCs. We also used antibo-
dies to detect a-tubulin (expressed predominantly in
leukocytes but less abundantly in RBCs), hemoglobin
(expressed exclusively in RBC) and Ficolin 1 (FCN1:
expressed exclusively in leukocytes; 15). To examine if
the leukocytes harboring the membrane proteins may
stick to filter fiber surfaces differentially and retained by
the filters, we also tested antibodies against leukocyte
specific membrane proteins such as CD14 and CD11a.
FCN1 is a soluble collagen-like protein that binds sugar
structures or acetylated compounds present on microor-
ganisms and initiates activation of the lectin comple-
ment pathway [15]. CD14 is a component of the innate
immune system that is either anchored into the leuko-
cyte membrane or in a soluble form [16]. CD11a is a
component of the Beta2-integrin CD11a/CD18 (LFA-1)
that is a leukocyte transmembrane protein [17].
We found that a-tubulin, FCN1, CD14, and CD11a
showed strong bands only when samples were passed
once through the 10-filtered LeukoCatch (Figure 6A,
lane 6) or 5 times through the 5-filtered LeukoCatch
(Figure 6A, lane 7), while GAPDH and Erk1/2 served as
loading controls (Figure 6A lanes 1-7). Thus, not only
the leukocyte soluble protein (FCN1) but also the
Figure 4 Effect of the filter number on the capture of PBMCs by the LeukoCatch. Indicated blood cells were counted by the Coulter
LH750 hematology analyzer, using human peripheral blood samples (N = 3) passed once through the LeukoCatch equipped with 0-10 filters. In
the 5 × 5 sample, the blood sample was passed 5 times through a 5-filtered LeukoCatch. NT, non-treated blood samples; WBC, white blood cell;
LY#, lymphocyte number; MO#, monocyte number; NE#, neutrophil number; PLT, platelet; and RBC, red blood cell.
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recovered into the collected samples, suggesting that
even a population of leukocytes carrying membrane pro-
teins do not stick to filter fiber surfaces differentially
and not retained by the filters. Notably, little hemoglo-
bin was left in the 10-filtered LeukoCatch (Figure 6A,
lane 6).
As expected from the results shown in Figure 5A, the
capture efficiency of these proteins was increased when
the sample was passed through twice rather than once
(Figure 6B, lanes 1, 2), but similar results were obtained
for passage frequencies of 2~5 times (Figure 6B, lanes 2-
5). Notably, after washing with PBS 5 times for a 3-
times passages through 5-filtered LeukoCatch (denoted
by 3/5), the intensities of the bands for all proteins were
dramatically reduced (Figure 6B, lane 6). Hemoglobin
apperared to be removed during these repeated passages
(Figure 6B, lanes 3-6).
When the PBS wash frequency was 2~5 times, the
intensity of the FCN1 and hemoglobin bands were dras-
tically reduced after 3~5 PBS washes (Figure 6C). These
results indicate that the best protocol for the practical
use of the LeukoCatch system is as follows; repeated (5
x) blood passages through a 5-filtered LeukoCatch with
two PBS washes.
We compared these results with those of an extract pre-
pared according to the conventional centrifugation of a
blood sample on Percoll. A 10-μL extract derived from 40
Figure 5 Effect of the passage frequency on the capture of PBMCs from blood through the LeukoCatch. Indicated blood cells were
counted using human peripheral blood samples (N = 3) that were passed 1-5 times through a 5-filtered LeukoCatch. NT, non-treated blood
samples; WBC, white blood cell; LY#, lymphocyte number; MO#, monocyte number; NE#, neutrophil number; PLT, platelet; and RBC, red blood
cell.
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of similar intensity as that of a 2-μL extract derived from
160 μL of blood using the centrifugation method (Figure
6B, lanes 7 and 8). This result suggests that the protein
recovery of the 5-filtered LeukoCatch was at least 4 times
better than that of the conventional centrifugation method.
We also compared the amount of captured hemoglobin
in the LeukoCatch without filters (Figure 6D, lanes 1~6)
and with five filters (Figure 6D, lanes 7~11). We found
that the band intensities of 2
-4 dilution (4.1, arrow) of the
former was similar to 2
-0 (= 1) dilution (3.6, arrowhead)
of the latter. This indicates that about 2
-4 or 1/16 dilution
of hemoglobin was attained by the LeukoCatch, namely,
more than 90% of hemoglobin was removed by the Leu-
koCatch. Comparison of the intensity of other bands
(arrows or arrowheads) also supports this conclusion.
Discussion
The present study reports a quick, easy, efficient, and
centrifugation-free purification system of leukocyte
Figure 6 Western blot analysis of captured PBMC extracts using anti-GAPDH, -a-tubulin, -FCN1, -CD14,- CD11a, -hemoglobin and
-Erk1/2 antibodies. (A) LeukoCatch was equipped with various numbers of filters. Analyzed samples were 10-μL extracts (from 40 μL of blood)
of PBMCs captured with the indicated numbers of filters in the LeukoCatch. In the 5 × 5 sample, the blood sample was passed 5 times through
a 5-filtered LeukoCatch. Horizontal arrow or asterisk indicates the band for CD14 or immunoglobulin, respectively. (B) Passage frequency of the
blood sample through the LeukoCatch was varied. Analyzed samples were 10-μL extracts of cells captured from the indicated number of
passages through the LeukoCatch filters. Lanes 1-5 reflect blood washed twice with PBS (see steps e to h in Figure 1B). Lane 6 (sample 3-5)
reflects blood washed 5 times with PBS. In lanes 7 or 8, a PBMC extract (2 μL from 160 μL blood or 10 μL from 0.8 mL blood) prepared by the
standard method for PBMC preparation using centrifugation in the presence of Ficoll [11] was analyzed. As for CD11a, 100 μg extract of Jurkat
cells was also examined using the same anti-CD11a antibody to confirm the identity of detected bands. (C) The number of PBS washes was
varied. Analyzed samples were 10-μL extracts of cells captured by the LeukoCatch after the indicated number of PBS washes. (D) Western blots
for estimation of the removed red blood cells from the filters by monitoring the captured hemoglobin. The leukocyte extract obtained by the
serial two-fold dilution of non-treated blood samples (lanes 1-6) or the leukocyte extract using the 5-filtered LeukoCatch (lanes 7-11) were
subjected to western blot and probed with anti-hemoglobin antibody. The bar graph in the lower panel shows the intensity of each band
measured by using the Image-J software. Numbers above the bars represent the mean values of band intensities from three independent films
of distinct exposure time of the western blots (1 min, 10 sec and 1 sec). Pairs of arrows or arrowheads represents the compared bands (see text).
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layers of Pall Leukotrap filters (Figure 1). The Pall Leu-
kotrap RBC inline filter system [12] permits the near-
complete depletion of leukocytes from blood [14]. This
filter system has been successfully applied to the bedside
preparation of leukocyte-depleted platelet concentrates
from whole blood or to remove exogenous infectious
prions and endogenous infectious agents from red cell
concentrates [18,19]. In the present study, the usefulness
of this filter was extended to the preparation of whole
cell extracts from tissue culture cells or leukocytes from
blood samples.
We first developed a novel tool called LeukoCatch
that consists of a layer of filters held at the bottom of a
syringe to capture leukocytes but not RBCs from a
blood sample (Figure 1). Using human macrophage
(MONO-MAC-6) cells, we determined the optimal filter
numbers (Figure 2) and passage frequencies (Figure 3)
for the LeukoCatch system. The system was then
applied to human blood. The most practical protocol
involved 2~5 passages through the 5-filtered Leuko-
Catch (Figure 1) with two PBS washes, followed by pro-
tein extraction with EB (Figures 4, 5 and 6). Western
blot analysis probed by a typical leukocyte protein FCN1
showed that the 5-filtered LeukoCatch showed at least 4
times better recovery rate of leukocytes than the sample
prepared by conventional centrifugation of a blood sam-
ple on Percoll (Figure 6B).
Although the Leukocatch system removes 90% of
hemoglobin (Figure 6D), it is still be a huge contami-
nant in these preparations, considering that hemoglo-
bin in RBC is at a concentration of 5 mM and about
half the volume of whole blood is RBCs. However,
western blot analysis using typical leukocyte proteins
displayed sharp bands without distortion of their
shapes (Figure 6A-C). Without this system, western
blot analysis using the whole blood would not be prac-
tical because hemoglobin represents the major part of
the total protein and hampers the detection of other
leukocyte proteins.
Notably, these leukocyte membrane proteins (CD14
and CD11a) were also recovered into the collected sam-
ples, suggesting that even a population of leukocytes
carrying membrane proteins is not retained by the fil-
ters. To increase the efficiency of present 30-40% (Fig-
ure 4 and 5), we can increase the number of stacked
filters or increase the volume of syringe. However, this
is practically unnecessary because the present system
already can provide the enough amount of leukocyte
extracts for 50 times western blots for typical leukocyte
proteins FCN1, CD14 and CD11a from 2 mL blood
sample, considering the results shown in Figure 6B
obtained by using 40 μL of blood samples (40 μL × 50 =
2mL).
Since the LeukoCatch system is simple, an automatic
machine may be easily developed for the large-scale pre-
paration of protein extracts from blood samples. Elution
of the trapped lymphocytes by flushing EB into the Leu-
kotrap filters (which are commonly discarded after bed-
side use) may yield useful lymphocyte extracts for basic
and clinical research. Since functional human lympho-
cytes can be recovered from Leukotrap filters by back-
flushing with cold PBS [20], LeukoCatch could also be
useful as a quick and easy tool for the recovery of live
lymphocytes.
Conclusion
Taken together, we conclude that LeukoCatch is useful
not only for diagnosis at the bedside but also for basic
research using blood samples or tissue culture cells. Nota-
bly, the protein recovery of the LeukoCatch was at least 4
times better than that of the conventional centrifugation
method, which indicates the advantage of this technique.
Methods
Analysis with MONO-MAC-6 cells
MONO-MAC-6 cells (DSMZ, Germany) were main-
tained in RPMI1640 medium supplemented with 20%
f e t a lb o v i n es e r u m( F B S ,H y C l o n e ,L o g a n ,U T ) ,1 0μg/
mL human insulin, 2 mM L-glutamine, 1 mM sodium
pyruvate, 100 U/mL penicillin, and 100 μg/mL strepto-
m y c i ni naC O 2 (5%) incubator at 37°C. Cells in the
logarithmic growth phase were used for experiments.
MONO-MAC-6 cells (2 × 10
6 cells/experiment) sus-
p e n d e di n5m Lo fm e d i u mw e r ep a s s e dt h r o u g h
(sucked-and-poured) twice by the LeukoCatch, and then
were divided into two tubes. One tube was subjected to
FACS analysis. The other tube was centrifuged twice at
190 × g for 5 min each at 25°C, with the pellet washed
with 2.5 mL PBS between centrifugations. After remov-
ing the supernatant, 25 μL of elution buffer (EB) [10
mM Tris-HCl (pH 7.5), 100 mM NaCl, 1% TritonX-100,
1 mM EDTA (pH 8.0), 0.1 mg/mL PMSF, 1 mM Aproti-
nin, 0.001 mg/mL Leupeptin, 0.001 mg/mL pepstatin A,
1m MN a F ,1m MN a 3VO4,a n d1 0m Mb-glyceropho-
sphate] were added to resuspend the pellet. Finally, 12.5
μLe a c ho fH 2O and 4× sample buffer (SB) [0.2 M Tris-
HCl (pH 6.8), 8% SDS, 0.2% bromophenol blue, 20% gly-
cerol, 10% beta-mercaptoethanol] were added. The final
suspension was used for western blot analysis.
Fluorescence activated cell sorting (FACS)
MONO-MAC-6 cells (2 × 10
6 cells/experiment) filtered
by the LeukoCatch were stained by the CycleTEST™
PLUS DNA Reagent Kit (BD Bioscience) according to
the manufacturer’s instructions. Samples were divided
into four tubes. Cells were counted four times for each
sample to obtain the mean value using a FACScalibur
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dently repeated twice.
Western blot analysis and antibodies
For western blot analysis, the cell extracts were boiled,
separated by 8% or 10% SDS-PAGE, and transferred to a
polyvinylidine difluoride (PVDF) filter (Millipore, Bedford,
MA). The filters were incubated with rabbit polyclonal
antibodies specific for ERK1/2 (Cell Signaling Technology,
Danvers, MA), GAPDH (Fitzgerald Industries Interna-
tional, Concord, MA), hemoglobin (MBL, Nagoya, Japan)
FCN1 (Atlas Antibodies AB, Sweden), CD14 (Abcam,
Cambridge, UK) or CD11a (Abcam). Then, the filter was
incubated with horseradish peroxidase-conjugated anti-rat
IgG (Amersham, Piscataway, NJ). Immunoreactive protein
bands were visualized using Renaissance™ chemilumines-
cence reagents (DuPont NEN, Boston, MA).
Application of LeukoCatch to blood samples
Blood samples (2 mL per tube) drawn from one of the
authors (H.N, male, age 58) into EDTA vacuum blood
collection tubes were sucked into the LeukoCatch syringe
and poured back into the tube. This process was repeated
for various numbers of times. Phosphate-buffered saline
(5 mL) in a fresh container was sucked into the Leuko-
Catch syringe and poured back into the container. This
process was repeated various times. Elution buffer (0.5
mL) was sucked into the LeukoCatch syringe and the dis-
solved protein extract was poured back to the tube. The
protein extract in the flow-through fraction was either
kept frozen at -80°C after addition of glycerol (20% final)
for long-term storage, or was stored at -20°C after addi-
tion of 4× SB for western blot analysis.
Hematology analysis of blood samples
The number of RBCs, platelets (PLTs), and WBCs in the
fresh blood samples treated with or without LeukoCatch
immediately after the blood was drawn were counted
with an LH 750 hematology analyzer (Beckman Coulter,
Fullerton, CA). Triplicate samples were counted.
Preparation of PBMC extract by standard method
Fresh venous blood (2-4 mL) in EDTA (as an anticoagu-
lant) was mixed with an equal volume of 2% dextran/
saline solution and incubated at room temperature for
30 min to precipitate the RBCs. PBMCs in the superna-
tant were purified by density-gradient centrifugation on
Percoll (density: 1.064 g/mL), and were subsequently
suspended in SB for western blot analysis.
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